p #60; 0.001. Data from [74]. Center for Inflammatory Bowel Disease, Division of Gastroenterology, Beth Israel Deaconess Medical Center and Harvard Medical School, 330 Brookline Avenue, Boston, MA ...

Interventional clinical trials in acute severe ulcerative colitis (ASUC) are characterized by substantial heterogeneity due to a lack of consensus in several key areas of trial design -- this impedes ...

In certain patients, JAK inhibitor rescue medications seem to be more effective, researche ...

Alvotech stated that it designed the study to evaluate the safety, tolerability, and immunogenicity profiles of AVT80 and ...

Upadacitinib shows sustained efficacy in UC, with over half maintaining clinical remission through 144 weeks in a phase 3 LTE study. Real-world data from the IBD-DACH study confirmed upadacitinib's ...

How Does Tremfya Work for Ulcerative Colitis? Tremfya is a monoclonal antibody that reduces inflammation. The main ingredient in Tremfya is a medicine called guselkumab. This medicine blocks a ...

A longer prednisolone tapering period is better than a shorter one at improving the rate of clinical remission in patients with moderate-to-severe ulcerative colitis.

Researchers have identified a gut-genetic interaction that could trigger an overactive immune response in the colon — offering one possible explanation for the pain and bleeding of ulcerative colitis, ...

Takeda presented promising data on its ulcerative colitis and Crohn’s disease drug Entyvio at the World Congress of Gastroenterology at ACG2017, Oct. 13 to Oct. 18 in Orlando, Fla. The data suggests ...

What Is Infusion for Ulcerative Colitis? If your doctor has recommended infusion therapy, this is probably because standard treatment hasn’t helped relieve symptoms caused by moderate-to-severe ...

Itolizumab demonstrated clinical efficacy after 12 weeks of treatment, achieving a clinical remission rate of 23.3% compared to 20.0% for adalimumab and 10.0% for placebo Itolizumab achieved key ...

Northwestern Medicine investigators have identified a surprising culprit in the progression of inflammatory bowel disease: a naturally occurring metabolic compound in the gut, according to a study ...